8-K filing — Cadrenal Therapeutics, Inc. (CVKD)
Filed: 2026-10-07 AccNo: 0001213900-26-107442 Size: 233 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Cadrenal Therapeutics Consolidates Multi-Indication Strategy For Cardiac Acute Critical Care Franchise, With Focus On CAD-1005 For Both HIT And CSA-AKI
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cadrenal Therapeutics Announces Strategic Review Including Potential Asset Sales Or Merger, Says It Received 'Strong Interest' From Potential Partners
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of 27 cents per
Cadrenal Therapeutics Announces FDA's Feedback At Type D Meeting For CAD-1005 Inhibitor To Treat Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced positive feedback